211 completed, 20 unknown, 12 withdrawn, 11 terminated. 94 Phase 3, 66 Phase 2, 62 Phase 4, 18 Not applicable, 16 Phase 1.
Follow Formoterol Fumarate: new trials by email Literature Review of Formoterol Fumarate trials Research Report on Formoterol Fumarate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 1252 | 2027-01-30 | 2026-10-26 |
| Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD) Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline) - COPD Exacerbation | Phase 4 | Not yet recruiting | University of Tennessee Graduate School of Medicine | 280 | 2026-11-12 | 2026-10-19 |
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-10-01 | 2026-10-23 | |
| BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation), Foster® 200/6 pMDI (BDP/FF-200/6 µg) - Asthma | Phase 4 | Recruiting | Chiesi Farmaceutici S.p.A. | 644 | 2026-06-28 | 2026-07-31 |
| Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil Administration of investigation drug, Administration of comparator - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-06-01 | 2025-12-18 | |
| Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma | Phase 2 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 150 | 2025-11-21 | 2026-09-08 |
| Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications Formoterol Fumarate 12 mcg (Foradil Aerolizer), Usual treatment - Thoracic Surgery, Postoperative Pulmonary Complications (PPCs) | Not applicable | Recruiting | Centre Hospitalier Universitaire, Amiens | 266 | 2025-07-31 | 2026-01-16 |
| Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg - Asthma, Asthma Patients | Completed | Chiesi Bulgaria | 281 | 2025-02-01 | 2026-03-19 | |
| Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale | Recruiting | Chiesi Hungary Ltd. | 800 | 2024-10-24 | 2024-11-22 | |
| Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. Budesonide-Formoterol treatment - Cough-Variant Asthma | Phase 4 | Completed | AstraZeneca | 1000 | 2024-10-18 | 2025-09-18 |
| Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD budesonide / glycopyrronium / formoterol - Chronic Obstructive Pulmonary Disease (COPD) | Completed | AstraZeneca | 10 | 2024-04-30 | 2025-12-22 | |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Budesonide/Formoterol Inhalation Powder in Adults With Asthma Budesonide and Formoterol Fumarate, Placebo of Budesonide and Formoterol Fumarate - Asthma | Phase 3 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 338 | 2024-02-21 | 2026-08-27 |
| IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator - COPD | Phase 4 | Withdrawn | AstraZeneca | 2024-01-19 | 2024-02-01 | |
| A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | AstraZeneca | 297 | 2024-01-11 | 2025-08-27 |
| U-LABA/ICS Effects on Exercise Performance, Formoterol Symbicort, Formoterol, Placebo - Exercise Performance | Not applicable | Completed | Morten Hostrup, PhD | 20 | 2024-01-05 | 2024-08-13 |
| Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ) - COPD (Chronic Obstructive Pulmonary Disease) | Phase 4 | Recruiting | University of Tennessee Graduate School of Medicine | 72 | 2023-12-05 | 2026-10-19 |
| Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure Vilanterol / Umeclidinium (25/62.5 mcg), Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg - COPD Bronchitis, Pollution Related Respiratory Disorder | Phase 4 | Unknown | National Institute of Respiratory Diseases, Mexico | 128 | 2023-11-15 | 2024-08-26 |
| A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 171 | 2023-10-24 | 2026-03-05 |
| Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device) - COPD | Unknown | Chiesi SAS | 500 | 2023-08-01 | 2024-03-13 |
Showing 20 of 263. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (135) · Asthma (102) · Emphysema (18) · Bronchitis, Chronic (14) · Bronchiolitis Obliterans Syndrome (5) · Bronchitis (5) · Motor Activity (4) · Respiratory Aspiration (4) · Cough-Variant Asthma (3) · Dyspnea (3) · Inflammation (3) · Bronchiolitis Obliterans (2) · Disease (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2)
AstraZeneca (56) · Chiesi Farmaceutici S.p.A. (27) · Dey (16) · Sumitomo Pharma America, Inc. (11) · Organon and Co (8) · Novartis Pharmaceuticals (7) · Boehringer Ingelheim (6) · Mundipharma Research Limited (6) · Novartis (6) · Pearl Therapeutics, Inc. (6) · Eurofarma Laboratorios S.A. (5) · GlaxoSmithKline (5) · Orion Corporation, Orion Pharma (4) · SkyePharma AG (4) · University of Tennessee Graduate School of Medicine (4)
United States (91) · United Kingdom (36) · Germany (33) · Poland (25) · China (20) · Hungary (20) · Canada (18) · Italy (17) · Spain (17) · Bulgaria (16) · Czechia (16) · Romania (16) · France (14) · Russia (14) · Denmark (13)
Esther Garcia, MD (10) · Catherine Bonuccelli (9) · Christer Hultquist, MD (3) · Colin Reisner, M.D. (3) · Arthur F Gelb, MD (2) · Brian Lipworth, MD (2) · Elliot Israel, MD (2) · Emir Festic, MD (2) · Esther Garcia, Ph.D. (2) · Lars-Goran Carlsson, MD (2) · Narongwit Nakwan, M.D. (2)
PMID 22329608, PMID 36472162, PMID 21227674, PMID 21397482, PMID 22206353, PMID 22334770, PMID 22560478, PMID 23932460, PMID 24290280, PMID 24953015, PMID 25044280, PMID 25045258, PMID 25187881, PMID 25950858, PMID 26233481, PMID 26343939, PMID 26717511, PMID 28558833, PMID 30077810, PMID 31827323, PMID 32848381, PMID 32943047, PMID 14680096, PMID 15215480, PMID 16164444, PMID 16304262, PMID 17046300, PMID 17296644, PMID 17556723, PMID 17890470, PMID 18042473, PMID 18258423, PMID 18363201, PMID 18655841, PMID 18804362, PMID 18972276, PMID 18977646, PMID 19124372, PMID 19208459, PMID 19229704, PMID 19663129, PMID 19808130, PMID 19897551, PMID 20040610, PMID 20109122, PMID 20170333, PMID 20418370, PMID 20463178, PMID 20522841, PMID 20580216
2009 (4), 2008 (3), 2023 (3), 2014 (2), 2015 (2), 2017 (2), 1UG3HL141722-01A1 (1), 2005 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), KL2TR002346 (1), UL1RR024150 (1), UL1TR002345 (1)